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The organic component of the bone matrix comprises 40% dry weight of bone. The 
organic component is mostly composed of type I collagen and small amounts of non-
collagenous proteins (NCPs) (10-15% of the total bone protein content). The small 
integrin-binding ligand N-linked glycoprotein (SIBLING) family, a NCP, is considered 
to play a key role in bone mineralization. SIBLING family of proteins share common 
structural features and includes the arginine-glycine-aspartic acid (RGD) motif and 
acidic serine- and aspartic acid-rich motif (ASARM). Clinical manifestations of gene 
mutations and/or genetically modified mice indicate that SIBLINGs play diverse roles 
in bone and extraskeletal tissues. ASARM peptides might not be primary responsible 
for the functional diversity of SIBLINGs, but this motif is suggested to be a key domain 
of SIBLINGs. However, the exact function of ASARM peptides is poorly understood. 
In this article, we discuss the considerable progress made in understanding the role of 
ASARM as a bioactive peptide. 
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The extracellular bone matrix, unlike most connective tissues, is physiologically 
mineralized, and constantly reconstructed (bone turnover) throughout life. Osteoblasts, 
the bone-forming cells, are derived from mesenchymal stem cells, while the bone-
resorbing osteoclasts originate from hematopoietic stem cells. Osteocytes are terminally 
differentiated osteoblasts embedded in mineralized bone and make up over 90% of bone 
cells that greatly outnumber osteoblasts and osteoclasts. Bone homeostasis is 
maintained by the balance between osteoblastic bone formation and osteoclastic bone 
resorption, and is closely correlated with the osteocytic cell-cell networks [1]. 
Therefore, any dysfunction in these cells alters bone mass and architecture. Bone 
formation proceeds via intramembranous and endochondral ossification. 
Intramembranous bone formation takes place when osteo-chondrogenic progenitor cells 
differentiate directly into osteoblasts, while endochondral ossification happens when the 
progenitor cells differentiate into chondrocytes to form a cartilage template that is 
subsequently replaced by bone. In both cases, osteoblasts actively participate in bone 
formation processes, such as extracellular matrix (ECM) deposition, matrix maturation 
and mineralization that is under the control of a multitude of local and systemic factors 
[2].  
 
The ECM in bone is composed of minerals, collagen fibers, water, noncollagenous 
proteins (NCPs), and lipids. Hydroxyapatite [Ca10(PO4)6(OH)2] is a naturally occurring 
form of mineral, in which the elements are substituted with carbonate, magnesium and 
others, depending on the diet and environment. Type I collagen is the most abundant 
component of bone matrix proteins and serves as a basic building block of the matrix 
fiber network. NCPs contain serum-derived proteins, proteoglycans, glycosylated 
proteins, g-carboxyglutamic acid-containing proteins, growth factors, and small 
integrin-binding ligand, N-glycosylated proteins (SIBLINGs) [3]. Human diseases 
and/or animal models show that along with the most abundant form of NCP that is 
osteonectin (approximately 2% of total protein of developing bone) [4], small amounts 
of NCPs, e.g., SIBLINGs [5-8] also contribute to the structural and biochemical 
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properties of the bone.  
 
The SIBLING family includes dentin matrix protein 1 (DMP1), dentin 
sialophosphoprotein (DSPP), integrin binding sialoprotein (IBSP, which encodes bone 
sialoprotein, BSP), matrix extracellular phosphoglycoprotein (MEPE), and secreted 
phosphoprotein 1 (SPP1, which encodes osteopontin, OPN). The encoding genes for 
these proteins are all located on human chromosome 4q21 and mouse chromosome 5q 
with similar exon structures, and these members are probably a result of early gene 
duplication and divergence [9]. The SIBLINGs are poorly conserved at the amino acid 
sequence level, while all of them are known as ECM proteins and defined by the 
conserved motifs. The RGD (Arg-Gly-Asp) motif and post-translational modification 
motifs that include casein kinase phosphorylation, glycosylation, and proteolysis, are 
reflected in the functional significance of these proteins. SIBLINGs rich in hydrophilic 
amino acids are likely to be extended and flexible structures in solution, and link 
extracellular protein-protein interactions with the intracellular cytoskeleton. Thus, it 
participates in cell migration, proliferation, differentiation and so on. Recently, it has 
been proposed that a new functional domain, acidic serine- and aspartate-rich motif 
(ASARM) acts as an inhibitor of matrix mineralization. SIBLING family members have 
been extensively reviewed before (see for example, [9, 10]), while roles of ASARM are 
controversial. Growing evidence indicates that ASARM peptide fragments may be 
biologically active and more than just a waste product of bone formation and resorption. 
In this article, we will focus on our current understanding of ASARM and discuss a 
possible role of this peptide in bone. 
 
 
2. DIVERSE FUNCTIONS OF SIBLING PROTEINS: SPP1 (OPN) vs. MEPE 
 
OPN is also known as bone sialoprotein I and early T-lymphocyte activation 1. The 
gene encoding this protein was first isolated in 1986 from the cDNA library of a rat 
osteosarcoma cell line (ROS17/2.8) [11]. In normal conditions, Opn is constitutively 
expressed in bone and kidney, and also detected in extraskeletal tissues/cells such as 
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epithelial cells of the gastrointestinal tract, gallbladder, pancreas, reproductive tract, 
lung, breast, salivary glands, sweat glands, ganglion cells [12], activated CD4+ T cells 
and macrophages [13]. OPN is a 33-kDa nascent protein (314 amino acids in human and 
297 amino acids in mouse) and goes through posttranslational modifications by 
glycosylation and phosphorylation, thereby increasing its molecular weight to 44-kD 
and over. Approximately 30 phosphorylation sites exist in this polypeptide, while their 
usage varies among tissues/cells. Full-length OPN can be cleaved by thrombin [14] and 
matrix metallopeptidase (MMP)-3 and MMP-7 [15]. It is also known that 
transglutaminase catalyzes formation of cross-linking of OPN to collagen calcium-
dependently [16]. Transcription factor nuclear factor kB signaling is involved in OPN 
activities (see for example,[17]). Thus, OPN exists both as an immobilized ECM 
molecule and as a cytokine in body fluids [18], and is involved in various biological 
activities including skeletal mineralization [8], bone remodeling [19], cell migration, 
and activation of immunocompetent cells [20, 21]. The above-mentioned OPN 
pathways are also supposed to be closely correlated with rheumatoid arthritis [22], 
allergic airway disease [23], and cancer cell progression (including transformation, 
invasion and metastasis) [9]. 
 
In comparison to OPN, there is limited information on MEPE. MEPE was identified 
from a cDNA library of hemangiopericytoma, one of mesenchymal tumors responsible 
for oncogenic hypophosphatemic osteomalacia (OHO) [24]. OHO sharers pathologic 
conditions with inherited hypophosphatemic rickets/osteomalacia (e.g., X-linked 
hypophosphatemia, XLH) [25]. As a common etiology in these diseases, circulating 
phosphaturic factor “phosphatonin” has been explored as a substrate for phosphate-
regulating neutral endopeptidase, X-linked (PHEX) in which loss-of-function mutations 
cause XLH [26]. Mepe is expressed in human [27] and mouse bone [25] and dentin 
[28], especially in fully differentiated mouse osteoblasts. The human MEPE gene 
encodes 525-amino acid protein that shares only 50% sequence identity with mouse 
counterpart consisting of 433 amino acids [25]. However, conserved motifs, such as 
RGD cell attachment sequence, a SGDG glycosaminoglycan attachment motif, N-
glycosylation sites, and multiple phosphorylation sites exist across these species [24, 
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25]. It is postulated that alternative splicing of the human MEPE gene results in multiple 
transcript variants. MEPE was initially thought to be a candidate for phosphatonin, a 
possible substrate for PHEX, while its biological properties are controversial.  
 
MEPE deficiency does not impinge serum phosphate levels in mice, and rather 
increases trabecular bone mass [5]. Overexpression of Mepe in mice driven by Col1a1 
2.3-kb promoter decreases bone volume and causes hyperphosphatemia via the 
upregulation of the renal sodium-dependent phosphate cotransporter Npt2a [29]. It is to 
be noted that in this transgenic model, Mepe is overexpressed not only in bone but also 
in kidney [29, 30]. Mepe is highly expressed in the bones of a mouse XLH model (Hyp) 
[25, 31], while PHEX fails to hydrolyze MEPE in a cell-free system [31]. Backcrossing 
Mepe-deficient mice onto Hyp mice fails to correct hypophosphatemia, demonstrating 
that MEPE is not phosphatonin [32]. In contrast, insect-expressed recombinant human 
MEPE (i-rhMEPE) is capable of causing hypophosphatemia and/or hyperphospaturia in 
mice [33] and rats [34], possibly by promoting intestinal phosphate uptake with the 
increased protein levels of NPT2a [35]. MEPE is in circulation in healthy adult and 
elderly humans, whose levels are correlated with those of serum phosphate, parathyroid 
hormone (PTH), and bone mineral density [36]. Serum MEPE levels appear to be 
mostly within concentrations less than 600 ng/ml in 114 normal human subjects [36], 
therefore, the effects of MEPE on phosphate homeostasis may differ between normal 
and pathological conditions. Also, the action of MEPE on osteoclasts is inconclusive, as 
no association is found in bone marrow cell cultures (inhibitory effect) [37] versus 
Mepe-null mice (no effect) [5].  
 
ASARMs 
ASARMs rich in aspartate and glutamate amino acid residues acquire a net 
negative charge, resulting in their ability to bind calcium ions and calcium-containing 
inorganic mineral crystals in bone, cartilage and teeth. Therefore, SIBLINGs/ASARMs 
may contribute to the formation of calcium phosphate/hydroxyapatite crystals positively 
or negatively. As described before, MEPE-ASARM exhibits less than 80 % of sequence 
similarity to other ASARMs [24]. Figure 1 shows the sequence alignments and 
positions between MEPE-ASARM and other SIBLING family members (DSPP, DMP1, 
 
 7 
BSP, and OPN), based on the 50% and more sequence identity in 14-19-residue 
overlaps. DSPP is mostly cleaved into two major proteins, dentin sialoprotein (DSP) 
and dentin phosphoprotein (DPP) [28, 38], and the latter contains a long repeat of 
ASARM and RGD motifs. A deletion of Dpp results in roughly similar Dspp-null 
mouse phenotypes exhibiting defects in dentin mineralization [39]. Unlike DSP, DPP 
appears not to be processed by matrix metalloproteinases [40], and thus the involvement 
of DPP-ASARM in mechanisms underlying Dpp-null dentin hypomineralization 
remains unclear. Observations of mice lacking Opn [8] but not Bsp [7] and Dmp1 [41] 
indicate the role of ASARM as an inhibitor of mineralization. Multiple active sites 
including ASARM are distributed differentially in the complete sequence of SIBLING 
family members, suggesting that not all ASARMs in these proteins may be equally 
active. In this respect, only OPN- [30] and MEPE-ASARMs (see below) have been 
examined so far. Phosphorylation of serine residues is also involved in its calcium 
binding activity, and rat bone OPN contains an average of eleven phosphorylation sites 
out of 29 potential sites [42]. Based on predicted phosphorylated residues in human 
OPN by NetPhosK 1.0 Server (http://www.cbs.dtu.dk/services/NetPhosK/), a maximum 
of three serine residues in human OPN-ASARM (OPN3(p)S-ASARM) may be 
phosphorylated (Figure 2). A synthetic peptide corresponding to OPN3(p)S-ASARM 
(synOPN3(p)S-ASARM) at the concentrations of 10 µM or more inhibits mineralized 
matrix formation in the mouse osteoblast cell line MC3T3-E1, which is abrogated by 
addition of mammalian-expressed soluble recombinant human PHEX (truncated PHEX 
lacking the membrane domain, rhsPHX). Phosphoserine in OPN-ASARM is necessary 
for this process and binding to synthetic hydroxyapatite. synOPN-ASARM with or 
without phosphoserine does not show significant effects on cell proliferation and 





As shown in Figure 2, MEPE-ASARM is highly conserved among mammalian 
species and exhibits a unique feature being location at the C-terminal end. 
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Phosphorylation of serine 514 (S514), S518, S520, and S522 in human MEPE-ASARM 
amino acid sequence is postulated to be in common with other species. MEPE appears 
to be cleaved at regions close to ASARM, in which cathepsin B produced by osteoblasts 
can act and result in release of an ASARM peptide fragment (with and/or without 
phosphorylation) into the skeletal microenvironment [31], and circulation [43]. 
Circulating levels of MEPE-ASARM and its accumulation in bone [43, 44] and dentin 
[45] are significantly higher in Hyp mice and patients with XLH, while this peptide is 
also located in the osteoid and young osteocytes of normal mouse bone [44]. Injections 
of synthetic hMEPE peptide fragment (AC-100, 242-264, 200 µg/kg/day and less), 
containing RGD and glycosaminoglycan-attachment motifs, over the calvariae for 5 
days increase bone formation in newborn mice [37]. Likewise, AC-100 (3 µg/ml) and 
E.Coli-derived ASARM-truncated rhMEPE has anabolic effects on rat calvaria cell 
cultures by promoting osteoprogenitor cell adhesion [46]. Thus, it is clear that MEPE-
ASARM does not participate in MEPE-dependent increase in bone formation. 
Intraperitoneal bolus injection of insect-expressed i-rhMEPE (400 µg/kg/30h) causes 
hypophosphatemia in mice possibly due to its inhibitory effect on renal phosphate 
reabsorption [33], this is in agreement with the results of transgenic mice 
overexpressing Mepe [29]. Daily subcutaneous injections of synMEPE-ASARM with 
phosphorylated S518, S520 and S522 (synMEPE3(p)S-ASARM, 5mg/kg/day) increase 
osteoid thickness and hypomineralization in calvariae and long bones [47]. Further, a 
continuous infusion of synMEPE3(p)S-ASARM (2mg/kg/day via osmotic pump) into 20-
week-old mice for 4 weeks decreases serum phosphate and renal Npt2a mRNA levels. 
However, it increases serum levels of fibroblast growth factor 23 (FGF23), a 
phosphaturic factor, and decreases levels of osteocalcin and OPN [48]. Implantation of 
Affi-Gel agarose beads soaked in synMEPE3(p)S-ASARM (2 µg/µl) in dental pulps 
delays wound healing in a rat injured dentin/pulp model [45].  
 
In vitro studies on rhMEPE and synMEPE-ASARM are complicated. Not only i-
rhMEPE (≥100 ng/ml) but also synMEPE-ASARM (human sequence, ≥60 ng/ml) 
without any phosphorylation inhibits mineralized matrix formation in the mouse 
osteoblast cell line 2T3 in the presence of bone morphogenetic protein 2 [33]. However, 
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nonphosphorylated synMEPE-ASARM fails to decrease mineralized matrix formation 
in mouse bone marrow stromal cell cultures [49]. Again, synMEPE3(p)S-ASARM (≥1 
µM) but not synMEPE-ASARM inhibit mineralized matrix formation in a MC3T3-E1 
mouse osteoblast cell line [44].  
 
 
4. CONSIDERATIONS FOR MECHANISM(S) OF MEPE-ASARM ACTIONS 
 
The precise mechanism(s) of MEPE-ASARM actions as above remain 
controversial. Since MEPE is originally identified in tumors involved in OHO and is a 
candidate for “phophatonin” [24], it is not surprising that MEPE decreases renal 
phosphate reabsorption [29, 33]. Under pathogenic conditions, excess amounts of 
MEPE can cause phosphaturia and hypophosphatemia, resulting in skeletal anomalies. 
However, it is notable that synMEPE3(p)S-ASARM can mimic these effects [47, 48], 
raising question about how synMEPE3(p)S-ASARM inhibits renal phosphate 
reabsorption and bone formation. The former issue remains poorly understood. Like 
MEPE, is synMEPE3(p)S-ASARM targeted to Npt2a? What are the signaling pathway(s) 
in MEPE- and MEPE-ASARM-target cells in kidney? Of the latter issue, there are 
inconsistent findings across studies; synMEPE3(p)S-ASARM inhibits mineralized matrix 
formation with no effect on cell proliferation and differentiation in MC3T3-E1 cells 
[44]. However, the synthetic peptide inhibits the expression of principal 
osteoblast/osteocyte-specific genes, such as Runx2, Phex, and Dmp1, while it increases 
Mepe and osteoprotegerin mRNA levels in mouse bone marrow stromal cells [49]. It is 
unclear whether the difference between the two is dependent on their lineage and/or 
developmental stage backgrounds or undefined reasons. If it does, how MEPE-ASARM 
regulates the expression of osteoblast/osteocyte-specific genes is notable. Whether 
phosphoserine in ASARM is necessary for its actions appears to be settled by recent 
reports including OPN-ASARM [30], but further studies are needed to evaluate the 
role(s) of nonphosphorylated ASARM (see below). The majority of the actions of 
synMEPE3(p)S-ASARM on bone formation may be facilitated during mineralization 
processes by inhibiting hydroxyapatite crystal growth [44]. This event totally coincides 
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with the chemical features (negatively charged amino acids) of ASARM as above. 
 
As described, MEPE has been postulated to be associated with PHEX [24]. 
Baculovirus-expressed rhPHEX fails to hydrolyze E.Coli-derived rhMEPE but protects 
MEPE protein from cathepsin B proteolysis in a cell-free system [31]. This finding is 
consistent with the increased levels of MEPE-ASARM in bone and circulating MEPE-
ASARM in Hyp mice [43, 44]. rhsPHEX interacts not only with i-rhMEPE but also 
with synMEPE-ASARM with and without phosphoserine, as measured by surface 
plasmon resonance analysis [47]. Both i-rhMEPE (Ki=2.1 nM) and synMEPE3(p)S-
ASARM (Ki=128.7 nM) inhibit rhsPHEX enzyme activity in a cell-free system and 
increase the expression of FGF23 in mouse bone marrow cell cultures [50]. On the 
contrary, rhsPHEX almost completely reverses the inhibitory effect of synOPN3(p)S-
ASARM on mineralized matrix formation in MC3T3-E1cells, and cleaves both human 
and mouse ASARM peptides (with and without phosphoserine) at the amide linkages 
between serine and glutamate or between serine and aspartate in a cell-free system [44]. 
A small synthetic PHEX peptide capable of binding to synMEPE3(p)S-ASARM also 
ameliorates the inhibitory effect of synOPN3(p)S-ASARM in mouse bone marrow cells 
[49]. Because i-rhPHEX fails to hydrolyze i-rhMEPE in a cell-free system [31], 
ASARM, a cleavage product of MEPE by cathepsin B [31] may be further processed by 
PHEX. Thus, MEPE-ASARM in the presence and absence of phosphoserine may 
interact with PHEX, while phosphorylation of certain serine residues in ASARM  (see 
above) may modulate its effects on bone formation. It may be needed to know more 
about nonphosphorylated versus phosphorylated MEPE-ASARM than phosphorylated 
MEPE-ASARM alone in vivo. Interestingly, MEME-ASARM is also involved in 
osteoclastogenesis [49], chondrogenesis [51] and odontogenesis [45].  
 
CONCLUSIONS 
Little is known about whether ASARM peptide fragment, a consensus sequence motif 
in SIBLING family members acts as a bioactive peptide. As summarized in Figure 3, 
MEPE-ASARM may inhibit bone mineralization primarily by binding to 
hydroxyapatite crystals through its negatively charged properties, while the peptide may 
interact with PHEX enzyme involved in phosphate metabolism. It is possible that 
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ASARM is also targets progenitor cells, such as osteogenic cells and dental pulp cells 
and regulates their development via an undefined mechanism. MEPE is processed, then 
nonphosphorylated and phosphorylated ASARMs are accumulated in bone, and released 
into circulation, suggesting that additional role(s) of ASARM. Further research is 






Figure 1. Amino acid sequence identity (%) between human MEPE-ASARM and other 
human SIBLINGs. Numbers show positions in the indicated amino acid sequences 
through the NCBI database. The asterisks denote identical amino acid residues. 
 
Figure 2. Predicted phosphorylation sites of human OPN and MEPE by casein kinase. 
Underlines indicate positions of ASARMs. Mouse, rat (OPN and MEPE), cattle and 
tarsier (MEPE) ASARMs are also listed. S (green) is phosphorylated by casein kinase I; 
S/T (red) are phosphorylated casein kinase II or I. Phosphoserines 106, 112 and 115 of 
human OPN and 514, 518, 520 and 522 of human MEPE are conserved among species. 
 
Figure 3. Possible actions of ASARM on bone. MEPE produced by osteoblasts can bind 
to cell membrane protein including integrin and extracellular matrix (ECM) and 
influence multiple cell activities. Osteoblast-derived cathepsin B cleaves MEPE, with 
the resultant release of ASARM peptide fragment. Not only MEPE but also ASARM 
interacts with PHEX, which may affect their own activities on each other. ASARMs 
with and without phosphoserine are degraded by PHEX, while the reduced activity of 
PHEX increases levels of ASARM in bone as well as in circulation. The accumulation 
of phosphorylated ASARM in bone that binds to hydroxyapatite and inhibits its crystal 
growth. Thus phosphorylated ASARM acts as an inhibitor of bone mineralization. 
Phosphorylated ASARM also regulates osteoblast-specific genes via an undefined 
mechanism, resulting in alteration of bone metabolism. As MEPE is, circulating 
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